Abstract
Background: Muco-epidermoid carcinoma (MECa) represents c.25% of salivary gland cancers. MECa is sub-classified by the presence/absence of the MAML2 gene rearrangement. However, this test is not in routine diagnostic practice in the UK. This pilot study was performed to optimise the ZytoLight® MAML2 Break Apart FISH assay as a diagnostic test within a UK tertiary centre diagnostic laboratory and characterise the clinical and pathological associations of MAML2 rearrangement.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
